June 4, 2012
Janssen Research & Development, LLC, a group company of Johnson & Johnson of the US, announced on May 31 that the company has filed a new drug application (NDA) with the US FDA for canagliflozin, a SGLT-2 (sodium-glucose co-transporter 2)...read more